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Abstract Several conditions are comorbid with migraine;
our review is focused on the relation between migraine,
and cerebrovascular and cardiovascular diseases. Despite
many studies showed an association between migraine and
patent foramen ovale, it is still not known whether its
presence might be causal for the migraine pathogenesis and
currently its closure cannot be recommended for migraine
prevention. On the contrary, conflicting epidemiological
data link migraine to arterial hypertension and the use of
antihypertensive agents acting on the renin-angiotensin
system sounds promising in migraine prevention. A com-
plex bidirectional relation exists between migraine and
stroke, and new evidences show a clear association
between migraine and coronary heart disease. In both
conditions, migraine represents a defined risk factor
although the magnitude of the risk varies across the dif-
ferent studies. However, since the risk is low in the general
population, it is not possible to identify which migraineurs
will develop a cardiovascular or a cerebrovascular event
making difficult to apply preventive measures.
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As reported in the literature, comorbidity may be defined as
the presence of any additional coexistent condition in a
patient with an index disease or as an association between
two different disorders that is more than coincidental [1].
According to Lipton and Silberstein [2] comorbidity may
arise by coincidence or selection bias, one condition may
cause the other, both conditions may be related to shared
environmental genetic risk factors, and the same environ-
mental or genetic risk factors may determine a brain state
that gives rise to both conditions. The presence of a
comorbidity may complicate the diagnosis because of the
overlapping symptoms [2].
We already reviewed the comorbid neuropathologies in
migraine [3]; this update includes the most recent advances
on cerebrovascular and cardiovascular comorbidities.
Migraine and patent foramen ovale
Patent foramen ovale (PFO), an interatrial communication
remnant of the fetal circulation, is due to the failure in the
fusion of the septum primum with the septum secundum.
Anatomically, the PFO comprises overlapping portions of
septum primum and septum secundum, acting as a 1-way
flap valve allowing right-to-left shunt when the pressure in
the right atrium is superior to the pressure in the left atrium
[4, 5]. The prevalence of PFO in the healthy adult popula-
tion is around 25%. Since the last decade evidences
cumulated showing that migraine and PFO are associated to
an extent that goes beyond what would be predicted by the
chance co-occurrence of two common conditions. In case–
control studies, migraine with aura has been found to be
associated with PFO in nearly 50% of cases that is twice the
figure usually reported in non-migraineurs [6–10] and in
patients with PFO migraine has been found twice as fre-
quently as in patients without PFO [11–13]. Right-to-left
cardiac shunt at rest through a PFO is more common in
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migraineurs with aura than in non-migraineurs control
patients with PFO [6] and patients with migraine tend to
have greater right-to-left shunts with respect to the non-
migrainous population [10] suggesting that interatrial
communication may play a role in the pathogenesis of
migraine. The mechanisms underlying this possible asso-
ciation have been postulated but never demonstrated.
Venous blood contains agents normally removed by pas-
sage through the lungs that can trigger an attack of migraine
if they reach the brain in sufficient concentrations; alter-
natively, long-term shunting of those agents may reduce the
threshold for migraine generation in the brain [14]. Such
observations do not obviously imply that PFO is the cause
of migraine, as only 50% of patients with migraine with
aura exhibit PFO and not all subjects with PFO have
migraine. However, patients with migraine who have large
right-to-left shunts tend to recognize those activities that
increase the extent of the shunt as a trigger of their migraine
attacks suggesting that the PFO might play a relevant role in
subjects with a constitutional susceptibility to migraine
[15]. Not all studies, however, support this hypothesis. The
recent Shunt-Associated Migraine (SAM) study showed
that the effect of right-to-left shunt on migraine features is
not relevant but patients with shunt-associated migraine had
a higher likelihood to have at least one first degree relative
affected by migraine suggesting a possible genetic linkage
between migraine and PFO [16]. Clarifying if a PFO plays
any role in migraine pathogenesis or if the association is
caused by a common inheritance but is not causal for
migraine is crucial. If the former hypothesis will be proved,
trials of PFO closure for migraine prevention would have a
rationale, in the latter case there will be no reason to close
the PFO to prevent migraine.
Closure of the PFO for migraine prevention
A variable proportion of patients who underwent PFO
closure for non-migraine indications reported cessation or
improvement of their migraine attacks after the procedure
[17–29] (Table 1). The effect was evident for patients with
migraine with (frequency reduced by 54%) or without
(frequency reduced by 62%) aura but not for patients with
non-migraine headaches [27]. Those studies are limited by
being predominantly retrospective, non-randomized, and
conducted in highly selected populations of patients. Fur-
thermore, the highly variable course of migraine and the
known placebo effect in previous migraine trials preclude
any conclusion.
The Migraine Intervention with STARFlex Technology
(MIST) trial was the first randomized controlled study
designed to assess the effect of PFO closure on migraine
headache in patients with frequent, disabling, and drug-
resistant migraine with aura [30]. In the trial, patients who
suffered from migraine with aura, experienced frequent
migraine attacks, had previously failed 2 or more classes of
prophylactic treatments, and had moderate or large right-
to-left shunts consistent with the presence of a PFO, were
randomized to transcatheter PFO closure with the STAR-
Flex implant or to a sham procedure. Patients were
followed up for 6 months. The primary efficacy end point
was cessation of migraine headache 91 to 180 days after
the procedure. One hundred forty-seven patients were
randomized. No significant difference was observed in the
primary end point of migraine headache cessation between
implant and sham groups (3 of 74 versus 3 of 73, respec-
tively; P = 0.51). Secondary end points also were not
achieved. On exploratory analysis, excluding two outliers,
the implant group demonstrated a greater reduction in total
migraine headache days (P = 0.027). As expected, the
implant arm experienced more procedural serious adverse
events; all events were transient. However, the results of
the MIST trial did not allow to definitely exclude any
benefit of the PFO closure. In fact, the included patients
were selected because they had particularly severe and
refractory migraine that is less amenable to treat than mild
or moderate migraine; the continued use of prophylactic
migraine medication throughout the trial in both treatment
arms may have limited the impact of PFO closure; and the
primary study end point of migraine cessation may have
been unrealistic and less clinically relevant than reduction
in migraine frequency since even the best-designed studies
of preventive medications show a responder rate (reduction
of migraine frequency C50%) of only around 50% [31].
According to the SAM study the presence of a right-to-left
shunt reduced the susceptibility to develop a migraine
attack following exposure to other triggers but enhanced
the likelihood of initiating an attack with an aura [16];
consequently, it should be tested the hypothesis whether
PFO closure may benefit auras rather than pain in migrai-
neurs. Finally, in the MIST trial, the benefits of PFO
closure were analyzed from 3 to 6 months after device
implant. The effect of PFO closure during this relatively
early analysis phase may have been confounded by clopi-
dogrel use, incomplete closure of the defect, concomitant
pulmonary shunt, and a possible early transient adverse
effect of device implant. Therefore, a longer analysis phase
might have demonstrated additional benefit accrued over
time. Residual shunts were assessed by the investigators
using contrast transthoracic echocardiography at 6 months.
However, it is likely that more residual shunts persisted
earlier during the analysis phase and atrial or pulmonary
shunts below the detection threshold of this technique
might have had an impact on the treatment effect in this
population.
Thus, there is insufficient evidence on the hypothesis
that migraine frequency is reduced by PFO closure. Further
238 J Headache Pain (2008) 9:237–248
123
properly conducted, prospective studies in migraine
patients including control groups with other or no head-
aches are underway in Europe and USA. Until then PFO
closure should not be used for the prophylaxis of migraine
[32].
Migraine and arterial hypertension
Despite the possible association between migraine and
arterial hypertension is an old issue, data still do not prove an
univocal interpretation of the co-occurrence of these two
conditions. In fact, several studies have explored a possible
association between migraine and hypertension, with con-
tradictory results. Some studies have shown a positive
association between migraine and hypertension [33–37],
others found no association while others found a negative
association between migraine and hypertension [38–47]
(Table 2). This fact may be attributed to differences in
methodology, the small sample size of some studies and to
some diagnostic inaccuracy in the characterization of the
various headache forms including migraine. Confusion may
arise also from the fact that hypertension may be an epi-
phenomenon of acute pain while, headache may be
associated with hypertensive encephalopathy as a conse-
quence of increased intracranial pressure, or may be reported
as a side effect of some antihypertensive treatments.
Antihypertensives for migraine prophylaxis
Beta-blockers that are drugs capable of lowering blood
pressure have been extensively used for migraine preven-
tion. More recently, drugs acting on the renin-angiotensin
system such as the angiotensin converting enzyme inhibi-
tors and the angiotensin II receptor blockers, have been
tested in migraine prophylaxis.
A double blind, placebo controlled, crossover study of
lisinopril 10 mg/day in 60 patients with migraine aged 19–
59 years with two to six episodes per month showed that
active treatment had a clinically important prophylactic
effect in migraine [48]. Hours with headache, days with
headache, days with migraine, and headache severity index
were reduced by 20, 17, 21, and 20%, respectively, with
lisinopril compared with placebo. Days with migraine were
reduced by at least 50%.
A randomized, double-blind, placebo-controlled cross-
over study of candesartan 16 mg/day in 60 migrainous
patients showed that the angiotensin II receptor blocker
provided effective migraine prophylaxis, with a tolerability
profile comparable with that of placebo. In detail, cande-
sartan reduced the number of days with headache including
hours with headache, days with migraine, hours with
migraine, headache severity index, levels of disability and
days of sick leave although there were no differences in
health-related quality of life [49].
Another small, open-label study showed that patients
with migraine and arterial hypertension or prehypertension
treated with olmesartan (10–40 mg/day) for at least
3 months reported an 82.5% average reduction in the fre-
quency of migraine attacks [50]. Patients also experienced
a 45% average reduction in the severity of migraine attacks
measured on a numeric pain scale of 1–10 [50]. Further
studies are needed to confirm the possible benefits of
olmesartan in patients with migraine.
The mechanisms underlying the benefits of drugs acting
on the renin–angiotensin system for migraine prophylaxis
are unknown. Whether the prevention of migraine is
attributable to the blood pressure reduction or to separate
pharmacological actions of the drugs other than lowering
blood pressure is still an unresolved issue. Angiotensin II is
a vasoconstrictor agent, increases sympathetic discharge
and adrenal medullary catecholamine release. Angiotensin
Table 1 Effect of patent foramen ovale closure on migraine in non-randomized studies in which the closure was performed for other reasons
than migraine















Anzola [17] 1 year 34 41 53 47 13 12
Azarbal [19] 3 months 75 40 5 40 20 20
Giardini [20] 1.7 years 83 – 9 – 8 –
Post [23] 6 months 75 57 NR NR NR NR
Reisman [24] 37 weeks 54 62 14 15 32 23
Rigatelli [25] 11 months 100 – 0 – 0 –
Schwerzmann [27] 1 year NR NR 79 90 21 10
Wilmshurst [28] 17 months 44 60 50 0 6 40
NR not reported
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is also involved in local brain functions mediated by the
type I receptors that include modulation of the cerebro-
vascular flow, effects on fluids and electrolyte homeostasis,
autonomic pathways, and neuroendocrine systems.
Migraine and cerebrovascular and cardiovascular
diseases
There are evidences that link migraine with ischemic stroke
and ischemic heart disease and potential mechanisms
accounting for their association. The association between
migraine and vascular disease of the retina has been also
reported.
Migraine and stroke
A complex bidirectional relation exists between migraine
and stroke including migraine as a risk factor for stroke,
migraine caused by stroke, migraine as a cause of stroke,
migraine and stroke sharing a common cause, migraine
mimicking stroke, and migraine associated with subclinical
Table 2 Selected studies evaluating the association between blood pressure, arterial hypertension and migraine
Study Design Diagnosis of
migraine
Evaluation of BP Results
Cirillo [33] Cohort study (age
16–64 years)
ICHD-I criteria Hypertension defined as
SBP C 140 mmHg and/or












Measurement of blood pressure.
Hypertension defined as
SBP C 160 mmHg and/or




Increased probability of having
migraine with increasing DBP
for women and decreased
probability of having migraine






Measurement of blood pressure Trend for decreased probability of
having migraine for higher SBP
in women but not in men. No





ICHD-I criteria Measurement of blood pressure.
Hypertension defined as
SBP C 140 mmHg and/or
DBP C 90 mmHg and/or use of
antihypertensives
No association between migraine
and arterial hypertension
Prudenzano [42] Cohort study ICHD-II criteria Hypertension defined as
BP [ 140/80 mmHg
Lower prevalence of hypertension






Measurement of blood pressure Increasing SBP was associated
with decreasing prevalence of
having migraine. For DBP, the




ICHD-I criteria Measurement of blood pressure.
Hypertension defined as
SBP C 140 mmHg and/or
DBP C 90 mmHg and/or use of
antihypertensives
Migraineurs had a lower mean
SBP than non migraineurs, a
lower pulse pressure, and a
lower mean DBP, although the
difference was not significant
for the latter. Significant trend
of decreasing frequency of




ICHD-I criteria Hypertension defined as
SBP C 140 mmHg and/or
DBP C 90 mmHg and/or use of
antihypertensives
Migraine was less frequent among
participants with hypertension.
SBP and DBP were lower in
migraineurs
BP blood pressure; SBP systolic blood pressure; DBP diastolic blood pressure; ICHD International Classification Headache Disorders
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stroke [3, 51]. Such possibilities were already extensively
reviewed and are summarized in Table 3 [3].
Numerous studies evaluated the association between
migraine and risk of stroke (Table 4) [51–72]. There is
good evidence that migraine with aura is associated with an
increased risk of ischemic stroke while data do not support
an univocal association between migraine without aura and
ischemic stroke [53]. The risk of stroke among migraineurs
is especially increased in young women with migraine with
aura, but is also apparent in older individuals. The
increased severity of the migraine attack is not associated
with an increased risk of ischemic stroke; on the contrary,
high frequency of attacks ([12 attacks per year) and a
recent onset of migraine (lifetime duration of \1 year
before the stroke event) are related to an increased risk
[62]. The risk of stroke in migraineurs is increased of more
than three times in the presence of cigarette smoking and of
more than four times in the presence of oral contraceptive
Table 3 Possible comorbidities between migraine and stroke
Type Definition
Migraine as a risk factor for stroke A clearly clinically defined stroke syndrome must occur remotely in time from a typical attack
of migraine
Migraine caused by stroke (symptomatic
migraine)
An acute vascular event in the central nervous system (ischemic or hemorrhagic stroke or TIA)
produces episodes of headache with the characteristics of migraine with or without aura; to
be coded as ICHD-II 6.1
Migraine as a cause of stroke (migrainous
infarction)
A documented infarct in a relevant area during the course of an attack of migraine with aura, in
a patient with a history of migraine with aura, with symptoms that are those of the aura and
in the absence of other possible causes at an extensive workup; to be coded as ICHD-II 1.5.4
Migraine and stroke sharing a common cause A syndrome (usually of genetic origin) in which both migraine and stroke are major clinical
features (e.g. CADASIL [ICHD-II 6.7.1] or MELAS [ICHD-II 6.7.2])
Migraine associated with subclinical stroke Evidence at brain neuroimaging of small areas compatible with brain ischemia in patients
without a history of any clinical symptom indicating a stroke syndrome
Migraine mimicking stroke (and viceversa:
stroke mimicking migraine)
Symptoms of migraine attacks (particularly aura without headache) and of stroke (particularly
TIAs) may overlap causing problems in the differential diagnosis
TIA transient ischemic attack, ICHD-II International Classification of Headache Disorders, Second Edition; CADASIL Cerebral Autosomal
Dominant Arteriopathy with Subcortical Infarcts and Leucoencephalopathy; MELAS Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-
like episodes











Buring [52]a, c 40–84 M 22,071 2.0, 1.1–3.6 NR NR
Carolei [53]a, d 15–44 M, W 899 1.3, 0.7–2.4 8.6, 1.0–75 1.0, 0.5–2.0
Chang [54]a, c 20–44 W 1,027 3.5, 1.3–9.6 3.8, 1.3–11.5 3.0, 0.7–13.5
Henrich [59]a, d 15–65 M, W 267 1.8, 0.9–3.6 2.6, 1.1–6.6 1.3, 0.5–3.6
Kurth [60]a, c C45 W 39,754 1.4, 1.0–1.9 1.7, 1.1–2.7 1.1, 0.7–1.8
MacClellan [62]a, c 15–49 W 1,000 NR 1.5, 1.1–2.0 1.0, 0.6–1.5
Marini [63]a, d 15–44 M, W 616 NR 14.8, 1.8–124 1.6, 0.9–3.0
Merikangas [64]b, c 25–74 M, W 12,220 2.1, 1.5–2.9 NR NR
Nightingale [67]a, c 15–49 W 1,319 2.3, 1.0–5.2 NR NR
Schwaag [68]a, d B45 M, W 320 2.1, 1.2–3.8 NR NR
Stang [70]a, c 45–64 M, W 12,750 NR 2.7, 1.6–4.6 0.8, 0.4–1.5
Tzourio [71]a, d 18–80 M, W 424 1.3, 0.8–2.3 1.3, 0.5–3.8 0.8, 0.4–1.5
Tzourio [72]a, c \45 W 245 3.5, 1.8–6.4 6.2, 2.1–18.0 3.0, 1.5–5.8
NR not reported; M men; W women
a Studies including only ischemic strokes
b Studies including ischemic and hemorrhagic strokes
c Adjusted risk
d Unadjusted risk
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use [54, 72]. The combination of migraine, oral contra-
ceptives, and smoking further increases the risk [54]. More
recent findings suggest that neither oral contraceptive use
nor smoking alone substantially increase the odds ratio of
ischemic stroke among women with migraine with aura
[62]. However, the combination of both, results in a ten-
fold increased risk of ischemic stroke when compared with
women without migraine who did not smoke and did not
use oral contraceptives [62], which is consistent with pre-
vious observations. Those data strongly indicate that
women with migraine with aura who use oral contracep-
tives should be strictly advised to quit smoking. Although
limited by small numbers, data indicate that the presence of
a PFO did not substantially increase the risk of ischemic
stroke among women with migraine with aura [62], sug-
gesting that its presence is unlikely to explain a large
amount of strokes in migraineurs. With regard to ischemic
stroke subtypes, the proportion of lacunar infarction and of
ischemic stroke of undetermined origin but not of athero-
sclerotic and cardioembolic strokes was higher among
women with migraine with aura than in non-migraine
stroke patients [62] suggesting possible alternative patho-
genic mechanisms in migraineurs.
Migraine may directly cause a cerebral ischemic event
(migrainous infarction, ICHD-II 1.5.4) [73]. This condition
is very rare and vastly over diagnosed [73]. Migrainous
infarction is considered a direct consequence of an
unusually severe hypoperfusion during the aura. To diag-
nose migraine-induced stroke the neurological deficit must
exactly mimic the migrainous symptoms of previous
attacks; the stroke must occur during the course of a typical
migraine attack; all other causes of stroke must be excluded
although stroke risk factors may be present [73]. Since
most strokes in migraineurs do not occur during the course
of migraine attack, this condition may account only for a
minority of strokes in migraineurs and may not account for
the increased risk of non cerebral events.
Migraine has also been associated with subclinical
vascular brain lesions [74, 75]. These lesions appear as
infarcts on magnetic resonance imaging even in the
absence of a clinical history of stroke. Lesions are partic-
ularly common in the posterior circulation vascular
territory [76–79]. Even in the absence of differences
between patients with migraine and controls in the overall
infarct prevalence (8.1 vs. 5.0%; P = 0.23), 8.1% of
patients with migraine with aura compared with 2.2% of
patients with migraine without aura and 0.7% of controls
(P = 0.05) had one or more lesions in the cerebellar region
[74]. Participants at the highest risk were those with
migraine with aura and at least one attack per month
compared with controls [74]. Traditional cardiovascular
risk factors and specific antimigraine medications did not
modify the association between structural brain changes
and migraine [74]. Specific small cerebellar border zone
infarct-like lesions were those mostly represented [75].
Patients with and without posterior circulation territory
infarct-like lesions did not present differences in cardio-
vascular risk factors [75] suggesting that, when present,
such lesions are not atherosclerotic in origin or reflect
small-vessel disease and that a combination of (possibly
migraine-related) hypoperfusion and embolism is the
likeliest etiological mechanism, although other mecha-
nisms could also play a role.
Migraine and retinal vascular disease
Case reports have linked retinal vein occlusions [80, 81]
and retinal infarctions [82, 83] to migraine. A population-
based study in a white Australian population (age 49 years
and older) reported smaller retinal arteriolar calibers
among persons with a history of migraine without aura as
compared with those without a history of migraine [84].
Recent results from the Atherosclerosis Risk in Commu-
nities (ARIC) Study indicate that middle-aged persons with
migraine and other headaches and without arterial hyper-
tension and diabetes mellitus were more likely to have
retinopathy signs including retinal hemorrhages (blot or
flame shaped), microaneurysms, soft or hard exudates,
macular edema, intraretinal microvascular abnormalities,
venous beading, swelling, or laser photocoagulation scars
[85]. The association was stronger in patients with
migraine with aura.
The retinal and cerebral microcirculations share similar
anatomy, embryology, and physiology. Since the retina is
more accessible than cerebral vessels, understanding the
mechanisms of the vascular disease of the retina might
provide important clues to clarify the relation between
stroke and migraine.
Migraine and coronary heart disease
While increased risk of ischemic stroke among persons
with migraine, and particularly with migraine with aura,
has been well established, the association between
migraine with aura and overall cardiovascular disease
including coronary heart disease has been long debated
[86–94]. Only recently, a clear association between
migraine and cardiovascular disease became evident [88,
89, 92].
A large cohort of more than 12,000 individuals partici-
pating in the ARIC study found an association between
migraine, and particularly migraine with aura, with Rose
angina that in the absence of a corresponding association
with coronary artery disease suggested that the association
between migraine and angina was not mediated by coro-
nary artery disease [92]. However, the ARIC study did not
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allow any conclusive evidence mostly due to a possible
bias related to the assessment of the headaches.
A prospective cohort of the Women’s Health Study
which included 27,840 US women aged 45 years or older
and that were free of cardiovascular disease and angina at
study entry showed that, after a mean of 10 years of fol-
low-up, active migraine with aura was associated with an
increased risk of cardiovascular events while the associa-
tion was not evident for patients suffering from migraine
without aura [88]. In detail, compared with women without
migraine history, women who reported active migraine
with aura had an increased risk for major cardiovascular
disease, ischemic stroke, myocardial infarction, coronary
revascularization, angina, and death due to ischemic car-
diovascular disease (Table 5) [88]. Patients who had prior
migraine were at increased risk only of coronary revascu-
larization and angina with respect to patients without
migraine [88].
A further prospective cohort study of 20,084 men aged
40 to 84 years participating in the Physicians’ Health Study
showed, with a mean follow-up of 16 years, that migraine
(any migraine including migraine with or without aura)
was associated also in the male sex to an increased risk of
cardiovascular disease. However, the detailed analysis of
the end-point events showed that this overall increased risk
was mainly driven by myocardial infarction while the risk
of ischemic stroke, coronary revascularization, angina, and
death due to ischemic cardiovascular disease was similar in
migraineurs and non-migraineurs (Table 5) [89]. However,
the association between migraine and ischemic stroke was
modified by age (P = 0.03), indicating an increased risk of
ischemic stroke for men with migraine who were 40–
54 years of age but not for those in the older age groups. In
this study, information on aura was not available hindering
any definitive conclusion about the possible different risk
between male patients suffering from migraine with or
without aura. A previous analysis of data from the same
population [86] did not reveal the positive association
found later [88, 89].
Mechanism linking migraine to cardiovascular
and cerebrovascular diseases
Accordingly, solid evidence supports the concept that
migraine, particularly migraine with aura is associated with
ischemic stroke and ischemic heart disease. Although it is
possible that in some individuals transient ischemic attacks
were misclassified as aura, this seems unlikely to account
for the increased risk. Moreover, triptan-induced chest pain
might have been misdiagnosed with angina in some cases
inducing a possible bias.
The mechanisms by which migraine either causes or co-
occurs with cerebrovascular and cardiovascular disorders
have remained cryptic and probably are rather complex. In
the past, mechanisms relying on protracted cerebral vaso-
constriction were postulated. Thereafter, an association
between migraine with aura and congenital heart defects,
particularly PFO, has been proposed as another potential
mechanism accounting for the increased risk of stroke in
migraineurs. Those possibilities, however, are unlikely to
explain the association between migraine and coronary
vascular events since they may explain the increased risk at
the cerebral level only. More correctly, migraine can be
considered a marker of a more wide systemic vascular
disorder. In fact, there is increasing evidence that in mi-
graineurs the vascular system not just in the brain but
outside as well is impaired [95, 96]. Brachial artery
diameter as brachial and femoral artery compliance were
decreased while aortic augmentation index (a parameter of
arterial stiffness that can be obtained from the central
arterial waveform as the ratio of augmentation pressure by
the reflection pressure wave to the pulse pressure) was
increased in migraineurs [96]. Subjects with migraine had
greater arterial stiffness than migraine-free subjects
Table 5 Multivariable-adjusted hazard ratios for ischemic vascular events according to migraine status in men and women according to data
from the Women’s Health Study [88] and the Physician’s Health Study [89]











Major cardiovascular event 1 2.15 (1.58–2.92) P \ 0.001 1.23 (0.88–1.73) P = 0.23 1 1.24 (1.06–1.46) P = 0.008
Ischemic stroke 1 1.91 (1.17–3.10) P = 0.01 1.27 (0.77–2.09) P = 0.36 1 1.12 (0.84–1.50) P = 0.43
Myocardial infarction 1 2.08 (1.30–3.31) P = 0.002 1.22 (0.73–2.05) P = 0.45 1 1.42 (1.15–1.77) P \ 0.001
Coronary revascularization 1 1.74 (1.23–2.46) P = 0.002 0.98 (0.67–1.42) P = 0.90 1 1.05 (0.89–1.24) P = 0.54
Angina 1 1.71 (1.16–2.53) P = 0.007 1.12 (0.75–1.66) P = 0.58 1 1.15 (0.99–1.33) P = 0.07
Cardiovascular death 1 2.33 (1.21–4.51) P = 0.01 1.06 (0.46–2.45) P = 0.89 1 1.07 (0.80–1.43) P = 0.65
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independently of other confounding factors including age,
sex, body height, blood pressure, and heart rate [97].
However, the precise mechanisms by which migraine may
lead to cerebrovascular and cardiovascular events remain
unclear. Several possibilities can be postulated to explain
the increased risk in migraineurs.
The first hypothesis relies on the fact that the increased
risk of vascular events can be due to a worst profile in terms
of vascular risk factors of migraineurs, and particularly of
migraineurs with aura, with respect to controls. The Genetic
Epidemiology of Migraine (GEM) study reported that,
compared to controls, migraineurs were more likely to
smoke, less likely to consume alcohol, and more likely to
report a parental history of early myocardial infarction [98].
Migraineurs with aura were more likely to have an unfa-
vorable cholesterol profile, to have elevated blood pressure,
to report a history of early onset coronary heart disease or
stroke, and had an elevated Framingham risk score; female
migraineurs with aura were more likely to be using oral
contraceptives [98]. Moreover, migraine frequency and
severity have been associated with increased body mass
index [99] and migraine, particularly migraine with aura,
has been associated with the methylenetetrahydrofolate
reductase C677T genotype [100, 101], which may lead to
hyperhomocysteinemia. Recently, compared with women
with no migraine history, women who reported any history of
migraine had modestly increased adjusted odds ratios for
elevated total cholesterol, for non-HDL cholesterol, for
apolipoprotein B100 and for C-reactive protein [102]. The
increase did not differ according to migraine aura status and
migraine frequency. The same study did not find any asso-
ciation between migraine and LDL cholesterol, HDL
cholesterol, apolipoprotein A-1, fibrinogen, soluble inter-
cellular adhesion molecule-1, homocysteine, and creatinine
[102]. However, the main limitation to the risk factors
hypothesis is that in the above reported studies as in other
studies most of the vascular risk factors were present in the
multivariate model which showed the association between
migraine and cerebrovascular and cardiovascular diseases
[70, 88, 89, 103]. In addition, several studies indicated that
the migraine–stroke association was present in the absence
of traditional vascular risk factors and that the type of stroke
was less frequently a large-vessel stroke or a small-vessel
stroke with respect to the general stroke population [62, 104].
Migraine has also been associated to an increase in
prothrombotic factors, including prothrombin factor [105,
106], factor V Leiden [107], and von Willebrand factor
[108]. The role of those uncommon vascular risk factors
remains to be clarified but probably they can be associated
only with a minority of vascular events.
The second hypothesis postulates that migraine patho-
physiology may affect the endothelial function and by this
alone or in combination with existing local vascular
pathologies may increase the vascular risk outside of a
migraine attack. The dysfunction of the endothelium, a
mechanical and biological barrier between the blood and the
vascular wall, implies a change of its homeostatic properties
in turn of procoagulatory, proinflammatory and proliferative
state which predisposes to atherogenesis [109]. Endothelial
dysfunction is characterized by reduction in bioavailability
of vasodilators (such as nitric oxide), increase in endothelial-
derived contracting factors, and consequent impairment of
the reactivity of the vasculature, including the microvascu-
lature; it represents the first step in the development of
atherothrombosis that finally leads to vascular events [109].
Traditional risk factors are known to cause endothelial dys-
function. There is also increasing evidence that migraine
may be a non-traditional risk factor for endothelial dys-
function [95]. In fact, prothrombotic, proinflammatory, or
other vasoactive peptides released during migraine may
damage the endothelium, leading to an increased risk of
atherosclerosis and vascular events. Endothelial dysfunction
is mediated by increased oxidative stress, an important
promotor of inflammatory processes [110]. Clinical inves-
tigation of markers of oxidative stress in a migraine
population during, after, and between migraine attacks has
yielded support for the association [111]. Moreover, cortical
spreading depression, a self-propagating wave of neuronal
and glial depolarization that has been implicated in the
genesis of aura [112] might be responsible of cellular and
molecular events, resulting in transient loss of membrane
ionic gradients, as well as massive surges of extracellular
potassium, neurotransmitters, and intracellular calcium.
Cortical spreading depression may mediate its effects in part
by altering the permeability of the blood–brain barrier via
activation of matrix metalloproteinases, a family of neutral
metalloproteases [113]. Their activation causes direct cel-
lular damage and the release of vasoactive neuropeptides
during migraine attacks that may stimulate inflammatory
responses within and outside the brain [114]. Reduced
endothelial repair capacity has emerged as another possible
connection between migraine and vascular disease [115].
Levels of endothelial progenitor cells, measured using flow
cytometry, were lower in migraineurs, and particularly in
those with aura, with respect to healthy controls and to
patients with tension-type headache; migraineurs presented
also increased markers of senescence and decreased migra-
tory capacity of endothelial progenitor cells. Endothelial
progenitor cells derive from bone marrow, circulate in
peripheral blood, are capable of proliferation and dif-
ferentiation into endothelial cells, and play a role in
neoangiogenesis after ischemia [116, 117]. Although it is not
known if the reduction of endothelial progenitor cells rep-
resents a primary alteration in migraine or the consequence
of migraine attacks, it might be possible that their alteration
mediates the increased vascular risk.
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The third hypothesis is that a vasospastic disorder may
give rise to both conditions. The finding in the ARIC study
that migraine was associated with Rose angina but not with
coronary artery disease suggests a further possible mech-
anism relying on a generalized vasospastic disorder
underlying both migraine and angina [92]. This possibility
is further supported by the finding that in women with
indications for coronary angiography, those with migraine
had less severe angiographic coronary artery disease than
those without migraine [118]. Moreover, cases of non-
atherosclerotic vasospam of the coronary arteries have
been documented in migraineurs with cardiac symptoms
[87, 89, 119].
The last hypothesis relies on an increased risk attrib-
utable to the different pharmacologic agents used to treat
migraine. Concerns have been raised regarding the car-
diovascular safety of the use of migraine medications,
especially triptans and compounds containing ergotamine,
due to their vasoconstrictive properties. However, recent
reviews of the clinical, pharmacological and post-mar-
keting cardiovascular safety data of triptans currently do
not support a direct association of these drugs with
ischemic vascular events [120, 121]. Moreover, data
referring to the association between migraine and stroke
date to the pre-triptans era. As migraine with and without
aura is similarly treated, this hypothesis seems unlikely
[122, 123].
Conclusion
Although migraine represents a clear vascular risk factor
the odds of risk can be considered small, especially in the
absence of concurrent vascular risk factors. To date, among
the huge population of migraineurs it is not possible to
recognize the subjects who will develop a vascular event. It
is currently unclear whether specific migraine features,
such as frequency or intensity, are associated with further
high risk of vascular events. In addition, it is currently
unknown if the treatment of migraine reduces the risk of
ischemic vascular events.
Nonetheless, for patients with migraine with aura, we
recommend heightened vigilance for and active control of
cardiovascular risk factors such as hypertension, hyperlip-
idemia, and smoking. Particular caution should be applied
in prescribing combined oral contraceptives in patients
with migraine with aura especially when they have addi-
tional risk factors which cannot easily be controlled [124].
Future studies should investigate the possibility that pre-
ventive medications for migraine or antiplatelet treatments
might modify the risk of vascular disease in subjects with
migraine and whether there are subgroups most likely to
benefit [123].
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